Sight Sciences Files 8-K with Regulatory Updates

Ticker: SGHT · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1531177

Sight Sciences, Inc. 8-K Filing Summary
FieldDetail
CompanySight Sciences, Inc. (SGHT)
Form Type8-K
Filed DateOct 17, 2025
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.001, $1,141.59
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-disclosure, financial-reporting

TL;DR

Sight Sciences dropped an 8-K, check it for Reg FD, other events, and financials.

AI Summary

Sight Sciences, Inc. filed an 8-K on October 17, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located in Menlo Park, California.

Why It Matters

This 8-K filing provides important updates and disclosures from Sight Sciences, Inc. to investors and the public regarding company events and financial information.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediately alarming or significant negative news.

Key Players & Entities

  • Sight Sciences, Inc. (company) — Registrant
  • October 17, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • Menlo Park, California (location) — Address of Principal Executive Offices
  • 877 266-1144 (phone_number) — Registrant's Telephone Number

FAQ

What specific events are disclosed under 'Other Events' in this 8-K filing?

The provided text does not detail the specific 'Other Events' but lists it as an item of information reported.

What is the SIC code for Sight Sciences, Inc.?

The Standard Industrial Classification (SIC) code for Sight Sciences, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

When is Sight Sciences, Inc.'s fiscal year end?

Sight Sciences, Inc.'s fiscal year ends on December 31.

What is the SEC file number for Sight Sciences, Inc.?

The SEC file number for Sight Sciences, Inc. is 001-40587.

What is the primary purpose of an 8-K filing?

An 8-K filing is used by publicly traded companies to disclose material events that shareholders should know about.

Filing Stats: 1,294 words · 5 min read · ~4 pages · Grade level 13.5 · Accepted 2025-10-17 07:05:41

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value per share SGHT The Nasdaq
  • $1,141.59 — e). The Medicare fee schedule amount of $1,141.59 is effective for dates of service on an

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 17, 2025, Sight Sciences, Inc. (the "Company") issued a press release announcing the establishment of jurisdiction-wide pricing for CPT code 0563T, which describes the procedure performed with the TearCare System and related accessories ("TearCare"), by Novitas Solutions, Inc. ("Novitas") and First Coast Service Options, Inc. ("FCSO"). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report"). On October 17, 2025, the Company posted an investor presentation to its website at https://investors.sightsciences.com/. The Company expects to use this investor presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts, and others. A copy of this investor presentation is furnished as Exhibit 99.2 to this Current Report. The Company plans to provide updated revenue and adjusted operating expenses guidance during its third quarter 2025 earnings call, taking into account the factors discussed in this Current Report.*

01 Other Events

Item 8.01 Other Events. Two Medicare Administrative Contractors ("MACs"), Novitas and FCSO, each established jurisdiction-wide pricing for CPT code 0563T (evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual expression, bilateral), which describes the procedure performed with the Company's TearCare System and related accessories (TearCare). The Medicare fee schedule amount of $1,141.59 is effective for dates of service on and after January 1, 2025, in all Novitas and FCSO jurisdictions and localities. The established local fee schedule is active for claim processing and is expected to be published on the Novitas and FCSO websites for reference by eyecare providers in these areas. TearCare procedure claims will be payable by First Coast and Novitas in the areas administered by them based on individual medical necessity determinations. The states and regions covered by these two MACs have 10.4 million in estimated total covered lives 1 . The Company plans to continue to engage with third-party payors, the clinical societies, and other stakeholders in continued support of patient access for interventional meibomian gland disease procedures performed with the TearCare System. 1 Covered lives estimate is derived from publicly available information and includes Medicare fee for service and Medicare fee for service - Medicaid Dual-Eligible beneficiaries. Cautionary Note Regarding Forward-Looking Statements This Current Report, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which statements are subject to considerable risks and uncertainties. The Company intends such forward-looking statements to be covered by the safe harbor provisio

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 17, 2025 99.2 Investor Presentation dated October 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * The information in Item 7.01 and Exhibit 99.1 of this Current Report shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act or Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sight Sciences, Inc. Date: October 17, 2025 By: /s/ Alison Bauerlein Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.